Jennifer K Harrison,1 Katherine S McArthur,2 Terence J Quinn21Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; 2Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UKAbstract: As stroke care has developed, there has been a need to robustly assess the efficacy of interventions both at the level of the individual stroke survivor and in the context of clinical trials. To describe stroke-survivor recovery meaningfully, more sophisticated measures are required than simple dichotomous end points, such as mortality or stroke recurrence. As stroke is an exemplar disabling long-term condition, measures of function are well suited as outcome assessment. In this review, we will describe funct...
<p>A measure of treatment effect is needed to assess the utility of any novel intervention in acute ...
Abstract—Although most current stroke intervention trials use disability scales to determine outcome...
BACKGROUND AND PURPOSE: The diversity of available outcome measures for acute stroke trials is ch...
As stroke care has developed, there has been a need to robustly assess the efficacy of interventions...
Background and Purpose-The Barthel Index (BI) and the Modified Rankin Scale (MRS) are commonly used ...
The effectiveness of therapeutic interventions in acute stroke trials is traditionally measured with...
The effectiveness of therapeutic interventions in acute stroke trials is traditionally measured with...
With stroke being the leading global cause of disability in adults, the use of clinical rating scale...
Introduction: A more than one third of stroke survivors are left with permanent disability in the fo...
Objective: The modified Rankin Scale (mRS) and the Barthel Index (BI) are the most common clinimetri...
Background and Purpose—Acute stroke trials typically use disability scales as their primary end poin...
Assessment of functional independence and residual disability is very important for measuring treatm...
Background and Purpose: The modified Rankin Scale (mRS) is the most widely used primary outcome meas...
Background and Purpose—The diversity of available outcome measures for acute stroke trials is challe...
The growing interest in documenting the effectiveness of rehabilitation has led to a progressive inc...
<p>A measure of treatment effect is needed to assess the utility of any novel intervention in acute ...
Abstract—Although most current stroke intervention trials use disability scales to determine outcome...
BACKGROUND AND PURPOSE: The diversity of available outcome measures for acute stroke trials is ch...
As stroke care has developed, there has been a need to robustly assess the efficacy of interventions...
Background and Purpose-The Barthel Index (BI) and the Modified Rankin Scale (MRS) are commonly used ...
The effectiveness of therapeutic interventions in acute stroke trials is traditionally measured with...
The effectiveness of therapeutic interventions in acute stroke trials is traditionally measured with...
With stroke being the leading global cause of disability in adults, the use of clinical rating scale...
Introduction: A more than one third of stroke survivors are left with permanent disability in the fo...
Objective: The modified Rankin Scale (mRS) and the Barthel Index (BI) are the most common clinimetri...
Background and Purpose—Acute stroke trials typically use disability scales as their primary end poin...
Assessment of functional independence and residual disability is very important for measuring treatm...
Background and Purpose: The modified Rankin Scale (mRS) is the most widely used primary outcome meas...
Background and Purpose—The diversity of available outcome measures for acute stroke trials is challe...
The growing interest in documenting the effectiveness of rehabilitation has led to a progressive inc...
<p>A measure of treatment effect is needed to assess the utility of any novel intervention in acute ...
Abstract—Although most current stroke intervention trials use disability scales to determine outcome...
BACKGROUND AND PURPOSE: The diversity of available outcome measures for acute stroke trials is ch...